Brief: Abivax Announces Acceptance Of 22 Abstracts Evaluating Obefazimod
17/12/2025 21:11
Dec 17 (Reuters) - Abivax SA ABVX.PA: EQS-NEWS: ABIVAX ANNOUNCES ACCEPTANCE OF 22 ABSTRACTS EVALUATING OBEFAZIMOD IN INFLAMMATORY BOWEL DISEASE AT ECCO 2026, FEATURING AN ORAL PRESENTATION ON PRECLINICAL ANTI-FIBROTIC FINDINGS Source text: ID:nEQ5j8xWKa Further company coverage: ABVX.PA ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Abivax SA
See all newsAbivax shares fall after rival drug data, trader says
France's Abivax H1 net loss widens on higher expenses driven by clinical programs
U.S. RESEARCH ROUNDUP-Caseys General Stores, Targa Resources, United Rentals
GS starts Abivax at 'buy,' sees multibillion sales potential for lead drug candidate
Europe's STOXX 600 ends week at all-time high on earnings support, soft US jobs data